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Abstract 
Introduction: Intense exercise places disproportionate strain on the right ventricle (RV) which 
may promote pro-arrhythmic remodelling in some athletes. RV exercise imaging may enable 
early identification of athletes at risk of arrhythmias.  
Methods and results: Exercise imaging was performed in 17 athletes with RV ventricular 
arrhythmias (EA-VAs) of which 8 (47%) had an implantable cardiac defibrillator (ICD), 10 
healthy endurance athletes (EAs) and 7 non-athletes (NAs). Echocardiographic measures 
included the RV end-systolic pressure-area ratio (ESPAR), RV fractional area change 
(RVFAC) and systolic tricuspid annular velocity (RV S’). Cardiac magnetic resonance (CMR) 
measures combined with invasive measurements of pulmonary and systemic artery pressures 
provided left ventricular (LV) and RV end-systolic pressure-volume ratios (SP/ESV), 
biventricular volumes and ejection fraction (EF) at rest and during intense exercise. 
Resting measures of cardiac function were similar in all groups, as was LV function during 
exercise. In contrast, exercise-induced increases in RVFAC, RV S’ and RVESPAR were 
attenuated in EA-VAs during exercise as compared with EAs and NAs (P<0.0001 for 
interaction group*workload). During exercise-CMR, decreases in RVESV and augmentation 
of both RVEF and RV SP/ESV were significantly less in EA-VAs relative to EAs and NAs 
(p<0.01 for the respective interactions). Receiver-operator characteristic curves demonstrated 
that RV exercise measures could accurately differentiate EA-VAs from subjects without 
arrhythmias [AUC for ΔRVESPAR =0.96 (0.89-1.00), P<0.0001]. 
Conclusion: Amongst athletes with normal cardiac function at rest, exercise testing reveals RV 
contractile dysfunction amongst athletes with RV arrhythmias. RV stress testing shows promise 
as a non-invasive means of risk-stratifying athletes.   
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Introduction 
Amongst endurance athletes, ventricular arrhythmias most frequently arise from the RV. Whilst 
these ventricular arrhythmias of RV origin are most often benign1, a significant incidence of 
major arrhythmic and fatal events have been described in some cohorts of athletes in association 
with structural, functional and electrical RV abnormalities2-4.  The accurate identification of 
those few athletes with a potential for life threatening arrhythmias remains a major clinical 
challenge. 
We have developed evidence supporting a hypothesis that the RV may be an “Achilles’ heel” 
of the endurance athlete’s heart.  Whilst the LV remains relatively unaffected, the RV has to 
withstand a disproportionate hemodynamic load during intense exercise5 resulting in transient 
exercise-induced RV dysfunction and chronic RV remodelling5-11. In a pre-clinical model, this 
exercise induced RV remodelling has been associated with a propensity to RV arrhythmias12.   
Using novel exercise echocardiography and real-time cardiac magnetic resonance (CMR) 
measures to assess RV function during exercise, we hypothesized that exercise could promote 
RV dysfunction in endurance athletes with ventricular arrhythmias (EA-VAs).  We compared 
EA-VAs with healthy endurance athletes (EAs) and non-athletic controls (NAs) with the aim 
of a) validating the pathophysiological concept of exercise-induced pro-arrhythmic remodelling 
in humans, and b) developing a non-invasive clinical tool for differentiating healthy athletes 
from those with a propensity to serious arrhythmias.  
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Methods 
Subjects 
Endurance athletes with ventricular arrhythmias (EA-VAs) were recruited from an existing  
cohort  at  our  institution  in  addition  to  new  cases  presenting  over  36 months. The following 
inclusion criteria had to be fulfilled: a) current or previous participation in competitive sport 
and an intensive exercise training regime (at least 3x2 h per week); b) RV arrhythmias excluding 
idiopathic RVOT-VT, required to have a monomorphic left bundle branch block morphology 
i) sustained, or ii) non-sustained for ≥3 beats at a rate of ≥120 beats per minute, or iii) frequent 
isolated premature ventricular beats ≥2000/day. Athletes were included if the heart appeared 
morphologically normal or had appearances consistent with “athlete’s heart”, which was 
considered to include mild structural or functional abnormalities of the RV given that such 
changes have previously been described in healthy endurance athletes5, 7, 11. Many of the athletes 
could be described by the syndrome “exercise-induced”2, 3 or “gene-elusive”4 arrhythmogenic 
right ventricular cardiomyopathy (ARVC) whereby there is: a) mild structural and functional 
abnormalities sufficient to meet Task Force Criteria for a clinical diagnosis of ARVC13, b) a 
protracted history of intense endurance exercise training and c) no evidence of inherited disease. 
Thus, all athletes underwent comprehensive evaluation and were excluded from participation if 
a mutation or variant of uncertain significance was identified in any of the five desmosomal 
genes associated with ARVC, or if there was clinical evidence of disease inheritance3.  Athletes 
with moderate or severe RV abnormalities were excluded as this is not typical of an exercise-
induced syndrome. Between 2011 and 2014, 25 athletes fulfilled the study inclusion criteria 
and 17 accepted to participate. Of these, 8 athletes had an implantable defibrillator (ICD). 15 
of 17 EA-VAs were treated with beta-blockers or non-dihydropyridine calcium channel 
blockers alone or in combination with anti-arrhythmic medications. These medications were 
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withheld for at least 24 hours prior to exercise testing. All eligible volunteers were male and 
therefore only male subjects were recruited as control subjects. 
The first 10 endurance athletes (EAs) responding to advertisements at local triathlon and 
cycling clubs who were competing in endurance sports and performing regular cycling and/or 
running training of >6 hours/ week were enrolled.  7 non-athletes (NAs) who were participating 
in recreational activity only (mild to moderate non-competitive exercise for <3 hours/week) 
were included. No subjects met exclusion criteria of known cardiovascular disease or 
abnormalities on ECG or echocardiogram. 
The study protocol conformed to the Declaration of Helsinki and was approved by the local 
ethics committee. All subjects provided informed consent. 
Study design 
Cardiopulmonary exercise testing was performed on an upright cycle ergometer (ER900 and 
Oxycon Alpha, Jaeger, Germany). Breath-by-breath analysis provided measures of oxygen 
consumption at peak exercise (VO2peak), ventilatory equivalent for carbon dioxide (VE/VCO2 
ratio) and maximal power output in Watts (Pmax).  In those subjects with an ICD, the device 
was re-programmed such that all pacing and shocks were suspended during the exercise testing 
and none of the athletes with an ICD were paced. Having previously demonstrated that 66% of 
Pmax corresponded to the maximal sustainable exercise intensity in a supine position14, we 
prescribed subsequent exercise efforts as: 25% (“low intensity”), 50% (“moderate intensity) 
and 66% (“peak intensity”) of Pmax.  
After at least 3 hours rest, echocardiography was performed at rest and during low-, moderate- 
and peak-intensity exercise using a programmable semi-supine ergometer with left lateral tilt 
(Easystress, Ecogito Medical sprl, Liege, Belgium).  
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The following day, all subjects (except the 8 EA-VAs with an ICD) underwent exercise CMR 
with simultaneous invasive pressure measurements. Prior to exercise, a 6 Fr pulmonary artery 
catheter was inserted under fluoroscopic guidance and a 20 gauge arterial catheter was placed 
in the radial artery. Pressure tracings were continuously acquired via a CMR compatible 
hemodynamic monitor (Maglife Serenity, Schiller AG, Baar, Switzerland).  
Echocardiography 
Resting and real-time exercise images were acquired using a Vivid E9 ultrasound system (GE 
Vingmed Ultrasound AS, Horten, Norway) and analysed offline using EchoPAC (version 112; 
GE Vingmed Ultrasound AS). Resting measures, including atrial and ventricular dimensions, 
early diastolic myocardial velocities and LVEF were acquired and analysed according to 
contemporary guidelines15, 16. RV outflow tract dimension (RVOTd) was measured in a 
parasternal short-axis view from the RV free wall to the aortic valve annulus and the RV inflow 
dimension (RVITd) was measured at the level of the tricuspid valve from an apical 
acquisition16. Two-dimensional global peak-systolic strain and strain rate (SRs) were quantified 
for the LV and RV on apical grey-scale images (60 – 90 frames/s) as described previously17. 
During exercise the following measures were obtained: a) LVEF and RVFAC from a single-
plane four chamber view as described previously17, b) RV free wall peak-systolic velocity (S’) 
by tissue Doppler imaging (frame rate, 120–160 frames/sec), and c) Systolic pulmonary artery 
pressure (PASP) from the maximal trans-tricuspid regurgitant velocities without addition of 
right atrial pressure estimates. Enhancement of the Doppler signal with agitated colloid 
enhancement was used in all subjects as described previously17. As a surrogate of RV 
contractility, the RV end-systolic pressure area relationship (RV ESPAR) was calculated as 
PASP divided by RV end-systolic area17. 
CMR equipment, image acquisition and analysis 
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Biventricular volumes were measured during supine cycling exercise using a real-time CMR 
method which we have previously validated against invasive standards14. In brief, subjects 
performed supine exercise within the CMR bore using a cycle ergometer with adjustable 
electronic resistance (Lode, Groningen, The Netherlands). Images were acquired with a Philips 
Achieva 1.5T CMR with a five-element phased-array coil (Philips Medical Systems, Best, The 
Netherlands). Steady-state free precession cine imaging was performed without cardiac gating. 
A stack of 13 – 18 contiguous 8 mm image slices was acquired in the short-axis plane and 
subsequently in the horizontal long-axis plane.  
Simultaneous with the image acquisition, ECG and respiratory timing were retrospectively 
synchronized using an in-house developed software program (RightVol, Leuven, Belgium) 
such that contouring could be performed at the same point of the respiratory cycle for all slices. 
Biventricular volumes were calculated from endocardial contours traced on the short-axis 
(SAX) image with simultaneous reference to the horizontal long-axis (HLA) plane thus 
enabling the analysers (GC and ALG) to confirm the position of the atrio-ventricular plane. 
Total pulmonary resistance (tPVR) was calculated as the ratio of mean pulmonary artery 
pressure (mPAP) to CO and total systemic vascular resistance (tSVR) as the ratio of mean 
systemic arterial pressure (mSAP) to CO. The end-systolic pressure-volume ratio (SP/ESV) 
was calculated as mPAP/RVESV for the RV and as (0.9*systolic blood pressure)/LVESV for 
the LV, as previously described18, 19.  NT-proBNP was analysed from venous blood samples.  
Statistical analysis 
Data were analysed using IBM SPSS statistics 22 software. Gaussian distribution of all 
continuous variables was confirmed using a Kolmogorov-Smirnov test and values are reported 
as meanSD or as median (25% and 75% percentile) as appropriate.. For clinical characteristics, 
comparisons between groups for continuous variables were performed by one-way ANOVA 
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whereas the Fisher’s Exact or χ2 test was used for categorical variables. A Mixed Linear Model 
with compound symmetric covariance matrix and the Bonferroni post-hoc test for multiple 
comparisons was performed to evaluate the LV and RV volume changes during exercise within 
and between groups. The interaction between group and workload was included to assess 
differences between groups. Receiver operating characteristic (ROC) curves were constructed 
and area under the ROC curves calculated20  to identify the best echocardiographic and exercise 
CMR methods for distinguishing athletes with VA from healthy subjects (expressed as area and 
95% confidence intervals). Resting, peak-exercise and delta (Δ – change from rest to peak) 
values were assessed. The significance of differences in area under the curve of the correlated 
rest and peak exercise ROC curves was tested using the methodology described by Delong et 
al.21   
Intra and inter observer variability of echocardiographic measures were assessed at rest and 
during the three exercise stages in 15 subjects.  The mean value of the two observations (x) and 
the absolute value of the difference between observations (e) ± SD were determined.  
Reproducibility was assessed by the coefficient of variation CV = (e/x) 100%, the intra class 
correlation coefficient (two-way mixed and absolute agreement quoted). A p-value <0.05 was 
considered statistically significant.  
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Results 
The demographic, clinical and exercise echocardiographic characteristics of the four study 
groups are presented in Table 1. Athletes in each group were of similar age but athletes with 
arrhythmias had competed in sports for longer and had higher BMIs at the time of the study.  
Healthy EAs had a higher VO2peak compared to the other groups, consistent with the fact that 
the EA-VAs had been advised to de-train. Sixty-five percent of the EA-VAs fulfilled the 
diagnostic Task Force Criteria for ARVC but none had evidence of familial disease or RV 
abnormalities that were considered moderate or severe. As detailed in Table 2, the EA-VAs 
who met major arrhythmia criteria for ARVC were more likely to have been treated with an 
implantable ICD (p<0.05) reflecting the likely influence that sustained ventricular arrhythmias 
of non-RVOT origin have on clinical decision making. The prevalence of other task force 
criteria abnormalities was similar between EA-VAs with and without ICDs. The putative risk 
factor of delayed enhancement on CMR (which is not a listed task force criterion) was observed 
in one ostensibly healthy EA and no more frequently in EA-VAs. Ventricular ectopy during 
cardiopulmonary exercise testing was less frequently observed in NAs but was similar in EAs 
and EA-VAs. Non-RVOT and variable morphology ectopics were similarly observed in all 
groups, whilst frequent ectopy and non-sustained VT were observed in EA-VAs without an 
ICD but not in those with an ICD (Table 2).  
Echocardiography at rest and during exercise 
There were few differences between the groups in resting cardiac measures (Table 3). As would 
be expected, cardiac volumes and dimensions were greater in the athletes, consistent with 
typical athletic cardiac remodelling.  However, there were no significant differences in 
functional measures of LV, RV or hemodynamic measures (LVEF, RVFAC, RV S’ and PASP) 
with the exception of RV strain rate which was reduced in EA-VAs as compared with healthy 
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EAs and NAs (P=0.002) and RV ESPAR which was reduced in EA-VAs as compared with 
NAs (P=0.011). EA-VAs had larger RV outflow tract dimensions than healthy EAs and NAs 
whilst RV inflow dimensions and atrial areas were similar amongst the athlete groups but larger 
than NAs. 
Echocardiographic measures were not obtainable in all subjects at peak exercise. Doppler 
myocardial velocities were obtained in all 34 subjects, LVEF and RVFAC in 32 subjects (94%) 
and RVESPAR in 24 subjects (71%). Despite this, peak exercise measures demonstrated 
significant impairment in RV reserve in EA-VAs, whilst LV measures were similar in all groups 
(Table 3). RV areas were greater whilst RVFAC and RV S’ were reduced in EA-VAs relative 
to both EAs and NAs.  These differences are more rigorously defined using repeated exercise 
measures (Figure 1). During exercise, LVEF augmentation was similar between all groups 
(interaction between within-subject changes during exercise vs. between-subject groups = 0.84, 
Figure 1A). In contrast, exercise-induced increases of RVFAC, RV S’ and RVESPAR were 
impaired in EA-VAs relative to EAs and NAs (P<0.0001 for interaction exercise*group; Figure 
1B, 1C and 1D). Within the group of EA-VAs, those with an ICD had lower RVFAC (36.0±8.1 
vs. 52.1±5.3 %; P<0.0001) and RV S’ (12.6±2.6 vs. 16.7±2.9 cm/s; P<0.0001) at peak exercise 
than those without ICD (P<0.0001). An example of exercise echocardiography comparing RV 
function in an EA and EA-VA is provided in Figure 2 and Video 1. 
NTproBNP did not correlate with resting LV strain (r=-0.31; P=0.09), resting LVEF (r= -0.086, 
P=0.6) or peak exercise LVEF (r= -0.026, P=0.9). In contrast, NTproBNP correlated modestly 
with resting RVFAC (r=-0.42; P=0.016), RV S’ (r=-0.44; P=0.012) and RV strain (r=-0.57, 
P<0.01) but a much stronger correlation was found between NTproBNP and peak exercise 
RVFAC and RV S’ (r=-0.78 and -0.71 respectively; P<0.0001; Supplementary Figure 1). 
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Echocardiographic measures of RV function, pulmonary artery pressures and cardiac output 
demonstrated excellent reproducibility.  Intra-class correlation coefficients ranged between 
0.93 and 0.997 for intra-observer variability and between 0.82 and 0.98 for inter-observer 
variability (Supplementary Table).   
CMR-derived cardiac volumes and invasive hemodynamics during exercise  
There were no differences in resting cardiac volumes between EAs and EA-VAs reflecting the 
fact that abnormalities in RV structure and function in the EA-VA group were, at most, mild. 
As expected, RV volumes in both groups were larger than NAs (P=0.01 and P=0.04, 
respectively). All resting hemodynamic measures were similar between groups (Table 4).  
During exercise, CMR measures were acquired in all subjects without ICDs. At peak exercise, 
RVEDV and RVESV were significantly larger and RVEF was reduced in EA-VAs relative to 
EAs and NAs – Table 4. When repeated exercise measures were assessed there was a clear 
difference between the effect of exercise on RV and LV measures in EA-VAs (Figure 3).  
Whilst LV function was similar between groups (Figure 3A, C and E), RV function was reduced 
during exercise.  Relative to EAs and NAs, the RV acutely dilated and failed to contract 
adequately, as demonstrated by a relative increase in RVEDV (interaction p=0.013, Figure 3B) 
and an attenuated decrease in RVESV (interaction P<0.0001, Figure 3D). As a result, RVEF 
augmentation was impaired in EA-VAs compared to healthy EAs and NAs (interaction 
P<0.001; Figure 3F). An example of exercise CMR comparing RV function in an EA and EA-
VA is provided in Figure 4 and Video 2. 
Increases in SV, HR, mPAP and SBP were similar between the different groups (Table 4). The 
mPAP/CO slope was similar in EAs, NAs and EA-VAs (0.92±0.42 vs. 1.11±0.46 vs. 1.23±1.1 
mmHg/l/min; P=0.64; Figure 5). On the other hand, the augmentation of RV SP/ESV was 
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reduced in EA-VAs compared to EAs and NAs (P=0.002 for interaction), again in contrast to 
the change in LV SP/ESV from rest to peak exercise that was similar between groups.  
As illustrated in Supplementary Figure 2, there was a strong correlation between 
echocardiography-derived RVESPAR and CMR-derived RV SP/ESV (r=0.84; P<0.0001).  
Impaired RV contractile reserve as a means of identifying arrhythmic risk 
ROC curves demonstrated that the ability of RV measures to accurately differentiate EA-VAs 
from healthy subjects (EAs and NAs) was relatively modest at rest using echocardiography 
[AUC for RV ESPAR=0.78 (0.61-0.95), RVFAC=0.72 (0.54-0.90) and RV S’=0.71 (0.53-
0.90), Figure 6A] but was impressive at peak exercise [AUC = 0.96 (0.89-1.00), 0.89 (0.78-
1.00) and 0.90 (0.79-1.00) respectively, Figure 6B). As compared to rest, this represented a 
significant improvement in AUC for RVESPAR (P=0.02) and a trend for improvement in 
RVFAC (P=0.052) and RV S’ (P=0.054).  In the cohort undergoing ex-CMR which excluded 
EA-VAs with an ICD, resting CMR measures did not differentiate athletes with arrhythmias 
[AUC for RVESV=0.59 (0.33-0.85), RVEF=0.55 (0.28-0.83), and RV SP/ESV=0.47 (0.15-
0.67), respectively, Figure 6C] whereas peak exercise measures did [AUC = 0.86 (0.70-1.00), 
0.78 (0.55-1.00), and 0.88 (0.74-1.00) respectively, Figure 6D]. This represented a significant 
improvement in AUC for all CMR measures at exercise relative to rest (P<0.05). An increase 
in RVESPAR <3.09 mmHg/cm2 from rest to peak-exercise had a sensitivity =83% and 
specificity =100%, whilst an increase in RV SP/ESV <0.25 mmHg/ml had a sensitivity =83% 
and specificity =88% for identifying athletes with RV arrhythmias.     
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Discussion 
Consistent with our hypothesis that pro-arrhythmic remodelling predominantly affects the RV, 
we demonstrated that athletes with ventricular arrhythmias develop RV dysfunction during 
exercise whilst healthy subjects do not. Importantly, this was evident despite there being few 
abnormalities at rest. This is of considerable clinical significance given that routine clinical 
assessment of athletes with suspected arrhythmias comprises cardiac imaging at rest, often with 
a focus on the LV. Our alternative strategy of focusing on the RV during exercise proved far 
more accurate in identifying athletes with potentially serious arrhythmias and offers 
considerable promise as a non-invasive risk stratification tool. 
Understanding the context of arrhythmias in athletes; the association with RV dysfunction 
Intense endurance exercise has been associated with disproportionate RV wall stress and RV 
injury5, 7, and we have hypothesized that this may serve as a substrate for complex RV 
arrhythmias22.  Given that the hemodynamic load on the RV is minimal at rest and increases 
disproportionately with exercise intensity5, 23, it stands to reason that exercise offers an 
opportunity to identify early or subtle RV dysfunction. Consistent with this premise, there were 
few differences between EA-VAs and EAs using conventional echocardiographic and CMR 
measures performed at rest. RVOT dimensions were slightly greater whilst RV systolic strain 
rate and RVESPAR were slightly lower in EA-VAs as compared with EAs but these measures 
were of relatively poor predictive value on ROC analysis.  On the other hand, every measure of 
RV function was reduced in EA-VAs during exercise and this was consistently demonstrated 
using both echocardiography and CMR. Exercise imaging also proved more useful than rhythm 
analysis given that ventricular ectopics were observed in healthy athletes and those with a 
predisposition to arrhythmias with equal frequency.  Paradoxically, frequent ectopics and non-
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sustained VT occurred in those athletes who had been considered at lower risk of sustained 
arrhythmias and had not been treated with an ICD.   
Real-time CMR performed during free breathing and strenuous exercise has been rigorously 
validated14 and has the advantage of providing simultaneous comparisons between LV and RV 
function. Thus, confidence can be placed in the divergence of ventricular function observed in 
EA-VAs during exercise. In the LV, augmentation of systolic function (reductions in LVESV 
and increases in LVEF) was similar between EA-VAs, EAs and NAs (Figure 3). In contrast, 
the reduction in RVESV and the increase in RVEF were significantly attenuated in EA-VAs 
relative to EAs and NAs. Thus, it can be concluded that the RV is disproportionately affected 
by exercise and our validation of this concept in humans agrees with pre-clinical rodent models 
in which endurance exercise promotes pro-arrhythmic remodelling of the RV, whilst sparing 
the LV12. 
Consistent with previous studies, we observed a near-linear relationship between pulmonary 
artery pressures and cardiac output (the so-called ‘P/Q relationship’)5, 23.  This current data 
represents the largest published description of invasively determined P/Q ratios in young 
healthy subjects and confirms that mean pulmonary artery pressures frequently exceed 
25mmHg at peak exercise (Figure 5). This represents a 2- to 3-fold increase in systolic load 
during exercise which is a far greater proportional increase than for the LV and could explain 
why the RV is most susceptible to exercise-induced dysfunction. 
Exercise echocardiography or CMR? 
Exercise-induced RV dysfunction in EA-VAs was consistently observed across imaging 
modalities. Furthermore, there was a strong inverse correlation between measures of RV 
function at peak exercise and NT-proBNP (Supplementary Figure 1) and also a strong 
correlation between RV contractility as determined by echocardiography and ex-CMR 
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(Supplementary Figure 2). Thus, the question arises as to which imaging technique is better.  
Despite expectations of more accurate quantification of RV function with exercise CMR, it did 
not prove better than echocardiography at identifying athletes with subtle RV dysfunction and 
arrhythmias (Figure 6). Given the widespread availability and cost-effectiveness of 
echocardiography, this is an important finding. Whilst a focus on RV measures is not commonly 
practiced, the measures employed in this study are relatively simple and could easily be 
included in clinical routine.  During exercise, RVFAC and RV S’ were obtained in the majority 
of subjects and could accurately identify athletes with arrhythmias (Figure 6B). The strongest 
echocardiographic measure was RVESPAR but its clinical utility may be limited by the fact 
that it was measurable in only 71% of subjects.  In contrast, high quality images can be acquired 
by Ex-CMR in virtually all subjects but the technique remains expensive and confined to few 
specialized centres. Although the areas under the ex-CMR ROC curves seemed inferior to those 
of echocardiography, direct comparison is limited by the fact that athletes with an ICD had to 
be excluded from CMR assessment. Thus, the ex-CMR study group was smaller and those 
athletes with the most profound exercise-induced RV dysfunction on echocardiography were 
excluded. Device exclusions would not be an issue for new presentations in which risk 
assessment is required and ex-CMR may be an extremely useful adjunct to standard resting 
CMR performed to exclude structural pathology in athletes with arrhythmias.  
Clinical utility of RV stress testing to identify athletes with arrhythmias 
It can be extremely difficult to determine the significance of palpitations, isolated ventricular 
extra-systoles or non-sustained VT in athletes, particularly when traditional cardiac imaging 
suggests that cardiac morphology and function are normal. From a population of 1644 screened 
athletes, Dello Russo et al. identified 17 athletes (1%) with frequent ventricular ectopy or non-
sustained VT but normal cardiac structure and function by conventional measures24. As a means 
of risk stratification electro-anatomical mapping and a guided ventricular biopsy was performed 
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revealing myocardial inflammation, fibrosis and/or fatty infiltrates in 13 of 17 athletes. RV 
angiography25 and inducibility during an electrophysiology study2 may also have some 
prognostic utility.  However, ventricular arrhythmias may be identified in 1-3% of endurance 
athletes1, 24 and the risks associated with these invasive techniques are not insignificant.  There 
is clear need for a non-invasive means of differentiating healthy athletes from those with 
potentially serious ventricular arrhythmias.  In this context, both exercise-CMR and 
echocardiographic RV stress testing show promise.  ROC curve analyses demonstrated that 
resting measures of RV function were poor at distinguishing athletes with complex arrhythmias 
from healthy subjects but that exercise measures were reasonably accurate (Figure 6).   
Current clinical recommendations suggest that the absence of structural heart disease is a 
critical factor in determining the athlete’s management and prognosis26 but the manner in which 
structural heart disease should be excluded has not been established. Echocardiography and 
CMR are frequently used in these settings but emphasis tends to be placed on LV measures and 
imaging is performed at rest.  Our current data suggests that this is a flawed practice with poor 
sensitivity for identifying athletes at risk of serious arrhythmias. We contend that exercise 
imaging with a focus on RV measures is a critical component of risk stratification in athletes in 
whom arrhythmias are suspected.  Furthermore, there is considerable overlap between the subtle 
RV changes described here in athletes and those which occur in other cardiac pathologies such 
as ARVC. As far as we are aware, there are no studies investigating the utility of exercise 
imaging for ARVC but our data provide strong rationale for such investigations. 
 
 
Limitations 
Our cohort was of modest size and comprised new cases of athletes with arrhythmias as well as 
cases previously assessed and managed at our institution. As a result, many of the athletes had 
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received treatment including detraining, anti-arrhythmics and ICDs. This introduces significant 
confounders in comparisons with the control subjects.  However, anti-arrhythmic, beta-blocker 
and calcium channel blocking medications were withheld for at least 24 hours prior to exercise 
testing; a period sufficient to exclude any persisting pharmacodynamic effect. Two athletes 
were treated were with low-dose Amiodarone which may have caused some negative 
chronotropic effect but would not have been expected to affect measures of biventricular 
function. As discussed previously, the exclusion of subjects with ICDs may have resulted in 
underestimation of the extent of RV dysfunction in the EA-VA cohort. Furthermore, there was 
significant heterogeneity amongst the cohort in terms of the burden and complexity of the 
arrhythmias, degree of RV remodelling and the amount of prior athletic training. Nonetheless, 
this represents the largest comparison of athletes with and without ventricular arrhythmias to 
date, and the only study to investigate exercise measures in this setting.  
Conclusions 
In endurance athletes, ventricular arrhythmias are associated with RV dysfunction which is 
most appreciable under the hemodynamic stress of exercise.  In athletes with ostensibly normal 
cardiac function at rest, echocardiographic and CMR measures of RV function performed 
during exercise show promise in being able to differentiate healthy athletes from those with a 
propensity to serious ventricular arrhythmias.     
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Table 1. Clinical characteristics 
 
Endurance 
athletes 
(n=10) 
Non-
athletes 
(n=7) 
Endurance athletes with 
ventricular arrhythmias 
(n=17) 
ANOVA 
p-value 
   
No ICD 
(n=9) 
ICD 
(n=8) 
 
Clinical 
Age (years) 35±6 34±16 39±8 40±9 0.57 
BMI (kg/ m2) 22.9±1.5 23.2±1.7 26.1±3.0 * 26.0±1.9 * 0.004 
Years of endurance 
sports 
9 (6-17) 0 (0-0) 21 (12-34) § 17 (8-20) § 0.002 
Hours per week 11 (6-15) § 0.6 (0-2) 11 (7-14) § 15 (14-21) § <0.0001 
ARVC Task Force Criteria 
Definite (2 major, 1 
major and 2 minor, or 4 
minor) 
  3 8 0.009 
Borderline (1 major and 
1 minor or 3 minor) 
  0 0 1.0 
Possible (1 or 2 minor)   6 0 0.002 
RVOT ectopics only‡   0 0 1.0 
Medications 
beta blockers - - 6 5  
calcium antagonists - - 2 0  
flecainide - - 0 2  
amiodarone - - 1 2  
sotalol - - 0 2  
cibenzoline - - 0 1  
Biochemistry 
NT-proBNP (pg/ml) 32 (12-43) 24 (5-37) 83 (21-294) 
132 
(68-218)*§ 
0.002 
Cardiopulmonary Testing 
VO2peak (ml/min/kg) 54.0±9.7 40.3±3.7 * 38.8±9.1 * 37.3±6.3 * <0.0001 
Peak power (Watts) 365±68 261±48 * 328±57 291±42 0.004 
Peak HR (bpm) 181±7 178±16 174±25 156±14 * 0.017 
VE/VCO2 (L/min) 0.026±0.003 0.024±0.004 0.027±0.003 0.027±0.004 0.2 
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Data presented as mean±SD or median (25% and 75% percentile); P-values from ANOVA 
using Bonferroni post-hoc test for multiple comparisons.  
* P<0.05 for difference vs. EAs; § P<0.05 vs. controls; † P<0.05 vs. EA-VA without ICD 
‡ In the absence of any other arrhythmias or structural abnormalities 
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Table 2.  ARVC Task Force Criteria and ectopy observed during exercise testing 
  
EAs 
(n=10) 
NAs 
(n=7) 
EA-VAs (n=17) 
 
    
No ICD 
(n=9) 
ICD 
(n=8) 
ARVC task force criteria details P-value* 
Global or regional 
dysfunction and structural 
RV alterations 
Major 0 0 1 4 0.13 
Minor 0 0 1 0 1.0 
Repolarization abnormality 
Major 0 0 3 4 0.64 
Minor 2 0 2 3 0.49 
Depolarization abnormality 
Major 0 0 0 0 1.0 
Minor NA§ NA§ 2 5 0.15 
Arrhythmias 
Major 0 0 3 7 0.049 
Minor 0 0 6 1 0.049 
Family History 
Major 0 0 0 0 1.0 
Minor 0 0 0 0 1.0 
Delayed enhancement on 
CMR 
NA† 1 0 1 2 1.0 
Ectopy observed during exercise testing P-value‡ 
Any Ectopics 5 1 8 6 0.016 
Non-RVOT morphology 3 1 3 4 0.41 
Multiple morphologies 0 0 1 0 0.41 
Frequent ectopy (>50 ectopics) 0 0 4 0 0.006 
Non-sustained VT 0 0 3 0 0.027 
EAs, endurance athletes; NAs, non-athletes; EA-Vas, endurance athletes with ventricular 
arrhythmias  
*P-value calculated for comparison between EA-VAs with and without ICDs 
‡ P-value calculated for comparison between all groups 
§NA – Not available: signal averaged ECGs were not performed in control subjects 
†Delayed enhancement on CMR is not a recognized task force criterion for ARVC 
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Table 3.  Echocardiographic measures at rest and during exercise 
 Endurance 
athletes 
(n=10) 
Non-athletes 
(n=7) 
Endurance 
athletes with 
ventricular 
arrhythmias 
(n=17) 
ANOVA 
p-value 
Rest 
HR (bpm) 52±8 62±12 55±9 0.220 
LV IVSd (mm) 9.7±3.4 9.7±0.7 10.6±1.1 0.184 
LV EDV (ml) 142±17 110±9 * 131±24 § 0.012 
LV ESV (ml) 55±10 47±5 55±17 0.333 
LVEF (%) 61.0±4.5 57.4±5.9 58.6±7.0 0.460 
LV strain (%) 19.7±2.6 17.7±2.3 18.1±2.8 0.200 
LV systolic strain rate (-/s) 1.14±0.20 1.13±0.07 1.0±0.12 0.050 
LV s’ (cm/s) 8.2±1.4 8.2±1.3 7.1±1.9 0.185 
RV diastolic area (cm2) 27.1±3.4 22.1±2.1 * 30.5±6.1 § 0.002 
RV systolic area (cm2) 14.7±1.6 11.6±1.5 18.1±5.1 *§ 0.002 
RVFAC, (%) 45.2±6.2 47.5±6.1 41.1±6.9 0.080 
RV strain (%) 26.0±2.5 27.8±2.0 23.8±4.6 0.050 
RV systolic strain rate (-/s) 1.51±0.22 1.61±0.19 1.28±0.22 *§ 0.002 
RV s’ (cm/s) 11.5±2.4 11.5±1.6 10.0±2.1 0.150 
TAPSE (mm) 30±5 25±4 26±4 0.070 
PASP (mmHg) 25±5 21±3 23±4 0.340 
RV ESPAR (mmHg/cm2) 1.7±0.4 1.9±0.4 1.4±0.4 § 0.011 
RVOTd (mm) 33±4 32±6 39±8 *§ 0.003 
RVITd (mm) 46±6 41±6 51±4 § 0.001 
Left atrial area (cm2) 21.1±3.6 15.8±2.5 * 20.3±2.7 § 0.002 
Right atrial area (cm2) 21.1±4.9 16.7±4.0 22.5±3.3 § 0.010 
Peak Exercise  
HR (bpm) 138±10 129±8 123±20 0.059 
LV EDV (ml) 127±22 102±13 122±22 0.050 
LV ESV (ml) 31±16 30±3 27±22 0.836 
LVEF (%) 74.2±5.9 70.9±2.3 69.3±8.5 0.290 
LV s’ (cm/s) 13.5±1.3 13.6±2.4 10.9±3.2 0.185 
LV e’ (cm/s) 16.9±2.8 15.6±2.8 13.6±3.7 0.363 
RV diastolic area (cm2) 25.8±2.2 20.9±1.9 30.5±6.2 *§ 0.001 
RV systolic area (cm2) 11.1±1.6 8.9±1.0 17.4±6.4 *§ 0.001 
RVFAC, (%) 57.1±5.2 57.0±5.2 44.1±10.6 *§ 0.001 
RV s’ (cm/s) 18.9±1.2 20.6±2.9 14.6±3.4 *§ <0.0001 
PASP (mmHg) 61±7 49±10 * 48±9 * 0.010 
RV ESPAR (mmHg/cm2) 5.7±1.1 5.6±1.5 3.0±1.2 *§ <0.0001 
 
*P<0.05 for difference vs. EAs; §P<0.05 vs. NAs. P-values from ANOVA using Bonferroni 
post-hoc test for multiple comparisons. 
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Table 4. CMR measures at rest and during exercise 
 Endurance 
athletes 
(n=10) 
Non-athletes 
(n=7) 
Endurance 
athletes with 
ventricular 
arrhythmias 
(n=9) 
ANOVA 
p-value 
Rest 
HR (bpm) 59±8 67±7 61±12 0.23 
CO (L/min) 8.1±1.0 7.4±1.5 7.7±1.7 0.63 
LVEDV (ml) 225±18 196±23 * 229±24 § 0.01 
LVESV (ml) 86±10 85±17 100±32 0.3 
LVSV (ml) 139±14 111±17 * 129±22 0.012 
LVEF (%) 61.8±3.3 56.6±5.9 56.8±10.2 0.22 
RVEDV (ml) 237±28 200±22 233±34 0.04 
RVESV (ml) 99±13 90±14 108±31 0.3 
RVSV (ml) 138±19 110±13 * 125±21 0.02 
RVEF (%) 58.0±2.9 55.1±3.7 54.1±8.1 0.29 
mSAP (mmHg) 96±7 89±7 93±6 0.11 
mPAP (mmHg) 14±4 11±2 15±4 0.09 
tSVR 964±152 984±181 1009±248 0.88 
tPVR 136±38 118±27 168±78 0.18 
Peak exercise 
HR (bpm) 161±12 151±9 149±25 0.30 
CO (L/min) 24.0±2.6 19.5±3.6 21.5±5.1 0.077 
LVEDV (ml) 218±14 186±25 * 224±19 § 0.001 
LVESV (ml) 65±16 57±10 79±28 0.096 
LVSV (ml) 153±17 129±18 145±21 0.055 
LVEF (%) 70.1±6.6 69.5±3.9 65.2±10.0 0.34 
RVEDV (ml) 214±28 179±22 * 237±27 § 0.001 
RVESV (ml) 67±19 52±10 95±30 *§ 0.002 
RVSV (ml) 147±22 127±17 142±24 0.19 
RVEF (%) 68.7±6.9 70.9±4.1 60.3±10.4 § 0.025 
mSAP (mmHg) 129±10 116±10 126±12 0.074 
mPAP (mmHg) 28±7 23±6 30±10 0.303 
tSVR 435±67 489±89 492±136 0.40 
tPVR 94±31 98±29 121±74 0.48 
 
*P<0.05 for difference vs. EAs; §P<0.05 vs. NAs.  P-values from ANOVA using Bonferroni 
post-hoc test for multiple comparisons.   
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Supplementary Table 1: Observer variability for echocardiographic exercise measures  
 Intra-observer Inter-observer 
 
CV, 
% 
Intra class 
correlation 
coefficient 
(95% 
Confidence 
Interval) 
Mean 
Difference 
±SD 
CV, % 
Intra class 
correlation 
coefficient 
(95% 
Confidence 
Interval) 
Mean 
Difference 
±SD 
LVOT VTI 
(cm) 
3.0 
0.98 (0.83 – 
0.99) 
0.74 ±0.7 2.1 
0.98 (0.95 – 
0.99) 
0.52 ±0.96 
RV EDA 
(cm2) 
8.6 
0.93 (0.14 – 
0.98) 
2.6 ±1.8 6.0 
0.90 (0.75 – 
0.95) 
1.8 ±3.1 
RV ESA 
(cm2) 
9.5 
0.95 (0.69 – 
0.98) 
1.6 ±1.7 12.3 
0.92 (0.60 – 
0.97) 
2.1 ±2.3 
RVFAC (%) 1.1 
0.93 (0.87 – 
0.96) 
0.50 ±4.8 8.0 
0.82 (0.66 – 
0.90) 
3.5 ±7.4 
PASP 
(mmHg) 
0.7 
0.997 (0.99 – 
1.00) 
0.24 ±1.36 1.5 
0.98 (0.97 – 
0.99) 
0.52 ±3.5 
RV ESPAR 
(mmHg/cm2) 
7.2 
0.99 (0.94 – 
0.99) 
0.17 ±0.22 6.5 
0.96 (0.93 – 
0.98) 
0.15 ±0.50 
RV S’ 
(cm/s) 
1.1 
0.97 (0.99 – 
1.00) 
0.15 ±0.50 2.6 
0.97 (0.95 – 
0.98) 
0.35 ±1.3 
 
CV, coefficient of variation; SD, standard deviation; LVOT VTI, LV outflow tract velocity 
time integral; RVEDA, RV end-diastolic area; RVESA, RV end-systolic area; RVFAC, RV 
fractional area change; PASP, systolic pulmonary artery pressure; RV ESPAR, RV End-
systolic pressure area relationship; RV S’, RV systolic annular velocity. 
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Figure legend: 
Figure 1. Echocardiographic measures demonstrating reduced RV reserve in athletes 
with arrhythmias. 
Changes in (A) LV ejection fraction (LVEF), (B) RV fractional area change (RVFAC), (C) RV 
peak systolic tricuspid annular velocity (RV S’) and (D) RV end-systolic pressure-area 
relationship (RV ESPAR) from rest to peak exercise. P values are shown for the interaction 
between group and exercise-intensity. At each exercise intensity, * P<0.05 for the difference 
between EA-VAs and EAs and § P<0.05 for the difference between EA-VAs and NAs. Error 
bars depict the standard error of the mean. 
Figure 2. Reduced exercise RV function in an athlete with arrhythmias as compared with 
normal exercise RV function in a healthy endurance athlete. 
End-systolic images of the RV are depicted at rest and at peak-exercise in a healthy endurance 
athlete (EA) and an athlete with ventricular arrhythmias (EA-VA).  There is a clear reduction 
in RV end-systolic area  from rest to peak exercise in EA resulting in an appropriate increase 
in RV fractional area change (RVFAC) whereas the RV area does not decrease in EA-VA and 
the RVFAC does not increase. The difference in RV augmentation is even better appreciated in 
video format (see Video 1). 
Figure 3. Magnetic resonance derived biventricular volume changes during exercise 
Changes in EDV, end-diastolic volume; ESV, end-systolic volume; and EF, ejection fraction 
during incremental exercise are shown for EA-VAs (red), EAs (green) and NAs (blue). P-values 
are shown for the interaction between group and exercise-intensity. At each exercise intensity, 
*P<0.05 for the difference between EA-VAs and EAs and § P<0.05 for the difference between 
EA-VAs and NAs. Error bars depict the standard error of the mean. 
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Figure 4. Reduced exercise RV function in an athlete with arrhythmias as compared with 
normal exercise RV function in a healthy endurance athlete. 
End-systolic images are depicted at rest and at peak-exercise in a healthy endurance athlete 
(EA) and an athlete with ventricular arrhythmias (EA-VA).  In EA, there is augmentation of 
both LV and RV function with exercise and the RV ejection fraction increases from 56% to 
74%. Resting RV function is similar in EA and EA-VA, but RV function fails to augment in 
EA-VA. The difference in RV augmentation is even better appreciated in video format (see 
Video 2). 
Figure 5. Relationship between mean pulmonary artery pressure and cardiac output. The 
relationship between mPAP and CO is similar for EAs, NAs and EA-VAs as indicated by the 
fact that there is no significant interaction between groups and the mPAP/ CO relationship.  
Error bars depict the standard error of the mean. 
Figure 6. Receiver-operating characteristic (ROC) curves for echocardiographic and 
CMR measures of RV function at rest and during exercise. 
Areas under curve (AUC) represent test accuracy in differentiating athletes with arrhythmias 
from healthy athletes and non-athletes. AUCs for RV fractional area change (RVFAC), RV 
peak systolic tricuspid annular velocity (RV S’) and RV end-systolic pressure-area relationship 
(RV ESPAR) improved from rest to exercise (Panels A and B, P≤0.05). Resting CMR measures 
(ESV, end-systolic volume; EF, ejection fraction; SP/ESV, end-systolic pressure volume 
relationship) could not differentiate a smaller cohort of athletes with arrhythmias from healthy 
subjects (Panel C), but all AUCs improved (P<0.05) and demonstrated good accuracy during 
exercise (Panel D).  
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Supplementary Figure 1. Correlations between B-type natriuretic peptide and RV 
function during exercise. 
Scatter plots and Pearson’s correlation statistics for the association between NTproBNP and 
(A) peak exercise RV fractional area change (RVFAC) and (B) RV peak-systolic velocity (RV 
S’). 
Supplementary Figure 2. Correlations between echocardiographic and magnetic 
resonance derived surrogates of RV contractility during exercise. 
Scatter plots and Pearson’s correlation statistics for the association between the 
echocardiographic RV end-systolic pressure area relationship (RVESPAR) and the cardiac 
magnetic resonance and invasive RV systolic pressure volume relationship (RV SP/ESV). 
 
Video 1. Reduced exercise RV function in an athlete with arrhythmias as compared with 
normal exercise RV function in a healthy endurance athlete – an echocardiographic 
example. 
Video 2. Reduced exercise RV function in an athlete with arrhythmias as compared with 
normal exercise RV function in a healthy endurance athlete – a CMR example. 
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Figure 1 
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Figure 2 
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Figure 3
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Figure 4 
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Figure 5 
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Figure 6 
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Supplementary Figure 1. Association between B-type natriuretic peptide and RV 
function during exercise. 
Scatter plots and coefficient of determination for the association between NTproBNP and (A) 
peak exercise RV fractional area change (RVFAC) and (B) RV peak-systolic velocity (RV S’). 
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Supplementary Figure 2. Association between echocardiographic and magnetic resonance 
derived surrogates of RV contractility during exercise. 
Scatter plots and coefficient of determination for the association between the echocardiographic 
RV end-systolic pressure area relationship (RVESPAR) and the cardiac magnetic resonance 
and invasive RV systolic pressure volume relationship (RV SP/ESV). 
 
 
